#United States #New York #Class Action #Kessler Topaz #uniQure N.V.

uniQure N.V. Class Action Lawsuit Overview

Investors who acquired ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, should be aware of an impending deadline for a class action lawsuit. Kessler Topaz Meltzer & Check, LLP, a noted law firm specializing in securities fraud cases, has initiated legal proceedings on behalf of these investors.

Key Details of the Lawsuit

The lawsuit, titled Scocco v. uniQure N.V., was formally filed in the United States District Court for the Southern District of New York. The essential contention within the complaint revolves around allegations of securities fraud against uniQure, specifically regarding material misstatements and omissions associated with their gene therapy drug for Huntington's disease.

Who's Affected?

Investors who have purchased shares during the specified period may find their interests aligned under this class action suit. The deadline for these investors to apply for lead plaintiff status is set for April 13, 2026. This status is critical, as it allows individuals to act on behalf of the larger class of affected individuals.

Allegations Against uniQure N.V.

The crux of the allegations against uniQure is that they failed to disclose critical information regarding their lead clinical program, AMT-130. This drug aims to treat Huntington's disease but has faced substantial scrutiny due to claims that the company misrepresented the progress of its clinical trials.

Among the numerous allegations, the following points are highlighted:

• - The FDA did not fully approve the design of essential clinical studies, which includes a comparison to external data sets that supposedly validated the trial results.
• - Despite claiming that significant progress was being made, uniQure may have to delay the submission of their Biologics License Application (BLA) for AMT-130.
• - Ultimately, statements made by uniQure regarding their operations and potential for success lacked a reasonable foundation, leading to a significant decline in investor trust and stock value.

Stock Impact

The class period culminated in a dramatic revelation on November 3, 2025, when uniQure disclosed to investors that the FDA had registered doubts about the adequacy of the clinical trial data supporting the drug's BLA submission. Following this announcement, uniQure's shares saw a staggering drop of over 49%, falling from $67.69 to $34.29 in one day.

Next Steps for Investors

For affected investors contemplating their legal options, Kessler Topaz Meltzer & Check, LLP offers a straightforward channel for communication. Interested parties can reach out to attorney Jonathan Naji to explore recovery options, free of charge. Investors can:

• - Contact KTMC to discuss their legal rights and options.
• - File to be designated as the lead plaintiff by the April 2026 deadline.
• - Choose to retain legal counsel or take no action and remain as part of the class.

The Lead Plaintiff Role Explained

The lead plaintiff is an essential figure in class action lawsuits, representing the collective interests of all class members. Typically, this individual or group will have the most significant financial stake in the outcome and will work with legal counsel to navigate the proceedings effectively.

Conclusion

With significant legal deadlines approaching, uniQure investors need to stay informed. Those eligible should consider their options carefully and consult with legal representatives to understand their rights and responsibilities in light of the class action lawsuit led by Kessler Topaz Meltzer & Check, LLP. For further inquiries, potential plaintiffs are encouraged to reach out via the details listed in the firm’s announcements.

For more information about uniQure N.V. and related class action suits, updates are provided by Kessler Topaz Meltzer & Check, LLP through their official channels.